Newsletter | May 28, 2025

05.28.25 -- Commercializing RNAi Therapies With Alnylam's Tolga Tanguler

FEATURED PODCAST

Commercializing RNAi Therapies With Alnylam's Tolga Tanguler

On today's episode, Tolga Tanguler, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals, talks about commercializing RNAi therapies, how they fit into health insurance reimbursement systems, the company's use of value-based contracts, and building therapeutic franchise "skyscrapers." Tanguler also shares his thoughts on commercializing RNAi therapies for larger patient populations, compared with rare disease populations, and reflects on changes in the biopharmaceutical sales and promotion model.

INDUSTRY INSIGHTS

Collaborative Approach Is Key To Successful CGT Clinical Trials

Cell and gene therapies offer hope for innovative treatments, but complex trials strain healthcare resources. Explore how the impact of resource strain delays these therapies for patients in need.

A 2025 Survey Report Uncovers The Top 5 Clinical Trial Cost Insights

In this 2025 survey of over 100 U.S. clinical trial participants and caregivers, we reveal that most individuals join trials seeking life-saving treatment, not financial gain.

A Proven AAV Platform To Drive Down Program Costs And Maximize Speed

To ensure that your adeno-associated virus (AAV) therapy reaches patients as soon as possible, begin your relationship with an experienced AAV manufacturer early in the development journey.

How Tech Solutions Can Power Your Commercialization Journey

The shift from startup to commercialization demands robust, scalable technology solutions such as ERP systems, which integrate essential functions into a single platform.

Reliable Proliferation And Differentiation Of Desired T Cell Subpopulations

This study evaluates a cost-effective alternative to Proleukin® for expanding T cells that demonstrates comparable performance across cell viability, subpopulation ratios, and clinical consistency.

Boosting Cell Culture Yields With Intensified Fed Batch Processing

Traditional fed-batch cell culture processes face limitations due to inherent cell line restrictions and accumulation of byproducts during the process, necessitating new approaches.